Clinical Trials Logo

Recurrent Gliosarcoma clinical trials

View clinical trials related to Recurrent Gliosarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02337686 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Start date: April 28, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects of pembrolizumab on the body, or pharmacodynamics, in patients with glioblastoma that has come back. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02192359 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Start date: March 7, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come back. Placing genetically modified neural stem cells into brain tumor cells may make the tumor more sensitive to irinotecan hydrochloride. Irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboxylesterase-expressing allogeneic neural stem cells and irinotecan hydrochloride may be a better treatment for high-grade gliomas.

NCT ID: NCT00102648 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Lonafarnib and Temozolomide in Treating Patients With Glioblastoma Multiforme That Is Recurrent or Did Not Respond to Previous Treatment With Temozolomide

Start date: December 21, 2004
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not respond to previous treatment with temozolomide. Lonafarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lonafarnib together with temozolomide may kill more tumor cells.